The first initial public offerings to launch on the Nasdaq in the wake of Facebook Inc.'s rocky debut drew little interest from investors Thursday. Biopharmaceutical company Tesaro Inc. ended its ...

GlaxoSmithKline to buy Tesaro for $5.1B Drug giant GlaxoSmithKline agreed to buy cancer treatment company Tesaro for about $5.1 billion including debt, according to CNBC.

TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that was acquired by Eisai Co., Ltd. in 2008 for $3.9 billion.

Boston, MA-based Tesaro was co-founded in March by former executives of MGI Pharma, an oncology and acute-care focused specialty biopharmaceutical company that was itself acquired by Eisai in 2008.

TESARO reported total revenue for the fourth quarter of 2017 of $48.0 million, compared to $4.9 million for the same period in 2016. Revenue growth was primarily driven by the launch of ZEJULA in ...

Comments TESARO, Inc. TSRO announced today that it has commenced an underwritten public offering of $100 million of its common stock. In connection with this offering, TESARO plans to grant the ...

Tesaro, at only a $2.4 B market cap and a pipeline, could be an attractive bolt-on acquisition for many large biotechs, and could be a rewarding stock on its own.

Tesaro shares jumped nearly 15 percent to $27.51 in premarket trading, after the company said the drug, rolapitant, achieved statistical significance over standard therapy in 532 cancer patients.